carteolol has been researched along with Body Weight in 11 studies
Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carteolol treatment increased beta-adrenergic receptor density, and the high carteolol dose restored SR Ca2+-ATPase and myofibrillar ATPase activities, along with creatine kinase, lactate dehydrogenase, aspartate transaminase, and ATP synthase activities, to normal." | 5.30 | Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. ( Bristow, MR; DiSalvo, TG; Gwathmey, JK; Hajjar, RJ; Khan, F; Kim, CS; Matsumori, A, 1999) |
| " The beta-blocking potency, estimated from the area under the dose-response curve (beta-blocking action) of carteolol, was also 300 times greater than that of propranolol and correlated well with the extent of the structural changes in the heart." | 5.27 | Dose-related inhibitory effects of the beta-adrenoceptor blocking drugs carteolol and propranolol on cardiac hypertrophy in spontaneously hypertensive rats. ( Igawa, T; Ikezono, K; Kimura, Y; Watanabe, K, 1984) |
| "Carteolol was shown to be safe and well tolerated by most patients." | 5.27 | Carteolol treatment of essential hypertension: a long-term study of safety and efficacy. ( Klepper, MJ; Luther, RR; Maurath, CJ; Peckinpaugh, RO; Ringham, GL, 1986) |
| "To determine whether beta blockade protects against the acceleration of lipid peroxidation in hyperthyroid rat soleus (slow-oxidative) muscle, in vivo chronic (3 weeks) effects of 3 beta blockers with different ancillary properties on mitochondrial oxidative enzymes, antioxidant enzymes, and thiobarbituric acid-reactive substances were investigated." | 3.68 | Differential effects of 3 beta blockers on lipid peroxidation in hyperthyroid muscle. ( Asayama, K; Dobashi, K; Hayashibe, H; Kato, K, 1990) |
| "Carteolol treatment increased beta-adrenergic receptor density, and the high carteolol dose restored SR Ca2+-ATPase and myofibrillar ATPase activities, along with creatine kinase, lactate dehydrogenase, aspartate transaminase, and ATP synthase activities, to normal." | 1.30 | Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. ( Bristow, MR; DiSalvo, TG; Gwathmey, JK; Hajjar, RJ; Khan, F; Kim, CS; Matsumori, A, 1999) |
| "Metoprolol did not cause any significant changes compared with the control group." | 1.28 | Beta-blocker treatment of dilated cardiomyopathy. Beneficial effect of carteolol in mice. ( Kawai, C; Matsumori, A; Okada, I; Tominaga, M; Yamada, T, 1991) |
| "Carteolol was added to the drinking water in doses of 0." | 1.28 | Systemic effects of carteolol, a beta-adrenoceptor antagonist in stroke-prone spontaneously hypertensive rats. ( Niwa, M; Ohkubo, T; Ohta, H; Ozaki, M; Shigematsu, K; Uchida, S; Yamashita, K, 1990) |
| " The beta-blocking potency, estimated from the area under the dose-response curve (beta-blocking action) of carteolol, was also 300 times greater than that of propranolol and correlated well with the extent of the structural changes in the heart." | 1.27 | Dose-related inhibitory effects of the beta-adrenoceptor blocking drugs carteolol and propranolol on cardiac hypertrophy in spontaneously hypertensive rats. ( Igawa, T; Ikezono, K; Kimura, Y; Watanabe, K, 1984) |
| "Carteolol was shown to be safe and well tolerated by most patients." | 1.27 | Carteolol treatment of essential hypertension: a long-term study of safety and efficacy. ( Klepper, MJ; Luther, RR; Maurath, CJ; Peckinpaugh, RO; Ringham, GL, 1986) |
| "Carteolol was administered orally by gastric intubation at 3, 15, 75 or 150 mg/kg/day to ICR-JCL mice of both sexes prior to mating and to females during early stage of pregnancy to determine its effects on the entire reproductive process and fetal development." | 1.26 | Reproduction study of carteolol hydrochloride in mice. Part I. Fertility and reproductive performance. ( Nakatsu, I; Shingai, F; Tamagawa, M; Tanaka, N, 1979) |
| "Carteolol was orally administered to mice once a day at doses of 3, 30 and 150 mg/kg/day during the perinatal and lactation periods and evaluated on its adverse effects on pregnant animals and their offspring." | 1.26 | Reproduction study of carteolol hydrochloride in mice. Part 2. Peri -and postnatal toxicity. ( Nishino, H; Numoto, T; Tamagawa, M; Tanaka, N, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (36.36) | 18.7374 |
| 1990's | 7 (63.64) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Igawa, T | 1 |
| Ikezono, K | 1 |
| Watanabe, K | 1 |
| Kimura, Y | 1 |
| Takahashi, H | 1 |
| Nakano, K | 1 |
| Yasuda, T | 1 |
| Komiyama, Y | 1 |
| Murakami, T | 1 |
| Nishimura, M | 1 |
| Nakanishi, T | 1 |
| Sakamoto, M | 1 |
| Nanbu, A | 1 |
| Yoshimura, M | 1 |
| Saitoh, Y | 1 |
| Tani, T | 1 |
| Asahi, Y | 1 |
| Man, Z | 1 |
| Kawano, K | 1 |
| Ikunaga, H | 1 |
| Gwathmey, JK | 1 |
| Kim, CS | 1 |
| Hajjar, RJ | 1 |
| Khan, F | 1 |
| DiSalvo, TG | 1 |
| Matsumori, A | 2 |
| Bristow, MR | 1 |
| Tanaka, N | 2 |
| Shingai, F | 1 |
| Tamagawa, M | 2 |
| Nakatsu, I | 1 |
| Numoto, T | 1 |
| Nishino, H | 1 |
| Tominaga, M | 1 |
| Okada, I | 1 |
| Yamada, T | 1 |
| Kawai, C | 1 |
| Asayama, K | 1 |
| Hayashibe, H | 1 |
| Dobashi, K | 1 |
| Kato, K | 1 |
| Hasui, K | 1 |
| Ohmoto, T | 1 |
| Tamaki, T | 1 |
| Fukui, K | 1 |
| Iwao, H | 1 |
| Abe, Y | 1 |
| Yamashita, K | 1 |
| Ohta, H | 1 |
| Uchida, S | 1 |
| Shigematsu, K | 1 |
| Ohkubo, T | 1 |
| Niwa, M | 1 |
| Ozaki, M | 1 |
| Luther, RR | 1 |
| Maurath, CJ | 1 |
| Klepper, MJ | 1 |
| Peckinpaugh, RO | 1 |
| Ringham, GL | 1 |
11 other studies available for carteolol and Body Weight
| Article | Year |
|---|---|
Dose-related inhibitory effects of the beta-adrenoceptor blocking drugs carteolol and propranolol on cardiac hypertrophy in spontaneously hypertensive rats.
Topics: Animals; Body Weight; Cardiomegaly; Carteolol; Dose-Response Relationship, Drug; Drinking; Heart Rat | 1984 |
Anti-obesity and anti-diabetic effects of carteolol in non-insulin-dependent diabetic mice.
Topics: Adipose Tissue, Brown; Animals; Blood Pressure; Body Weight; Carbohydrate Metabolism; Cardiac Output | 1994 |
Improving effect of carteolol on bodyweight and carbohydrate and lipid metabolic responses in the OLETF rat.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Animals; Blood Glucose; Body Weight; Carteolol; Cholest | 1997 |
Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol.
Topics: Adenosine Triphosphate; Adenylyl Cyclases; Adrenergic beta-Antagonists; Animals; Blood Pressure; Bod | 1999 |
Reproduction study of carteolol hydrochloride in mice. Part I. Fertility and reproductive performance.
Topics: Animals; Behavior, Animal; Body Weight; Bone Development; Carteolol; Feeding Behavior; Female; Ferti | 1979 |
Reproduction study of carteolol hydrochloride in mice. Part 2. Peri -and postnatal toxicity.
Topics: Animals; Animals, Newborn; Body Weight; Carcinogens; Carteolol; Feeding Behavior; Female; Fetus; Ges | 1979 |
Beta-blocker treatment of dilated cardiomyopathy. Beneficial effect of carteolol in mice.
Topics: Adrenergic beta-Antagonists; Animals; Body Weight; Cardiomyopathy, Dilated; Carteolol; Drug Evaluati | 1991 |
Differential effects of 3 beta blockers on lipid peroxidation in hyperthyroid muscle.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Body Weight; Carteolol; Hyperthyroidism; Lipid Perox | 1990 |
Effects of prolonged treatment with beta-adrenoceptor antagonist, carteolol on systemic and regional hemodynamics in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Cardiac Output; Carteolol; Cerebrovascular Disorders; Hemodyna | 1991 |
Systemic effects of carteolol, a beta-adrenoceptor antagonist in stroke-prone spontaneously hypertensive rats.
Topics: Adrenal Glands; Adrenergic beta-Antagonists; Animals; Aorta, Abdominal; Blood Pressure; Blood Urea N | 1990 |
Carteolol treatment of essential hypertension: a long-term study of safety and efficacy.
Topics: Adult; Aged; Body Weight; Carteolol; Electrocardiography; Female; Humans; Hypertension; Male; Middle | 1986 |